Standardizing the Benefit-Risk Assessment of New Medicines

  title={Standardizing the Benefit-Risk Assessment of New Medicines},
  author={L. Liberti and J. McAuslane and S. Walker},
  journal={Pharmaceutical Medicine},
  • L. Liberti, J. McAuslane, S. Walker
  • Published 2012
  • Medicine, Business
  • Pharmaceutical Medicine
  • Pharmaceutical scientists and healthcare professionals participating in the development of new medicines bring important practical perspectives to the evaluation of benefits and risks. Within pharmaceutical companies, these specialists can serve to inform the benefit-risk (BR) assessment process, particularly in the latter stages of drug development. However, pharmaceutical scientists may not be aware of the current state of activity in the ongoing efforts to standardize the BR assessment… CONTINUE READING
    6 Citations

    Figures, Tables, and Topics from this paper


    Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
    • 130
    Benefit-Risk Appraisal of Medicines: A Systematic Approach to Decision-making
    • 30
    • PDF
    Measuring Benefit and Balancing Risk: Strategies for the Benefit–Risk Assessment of New Medicines in a Risk‐Averse Environment
    • 34
    Refining the Benefit–Risk Framework for the Assessment of Medicines: Valuing and Weighting Benefit and Risk Parameters
    • 25
    • PDF
    A Multiattribute Model for Evaluating the Benefit-Risk Profiles of Treatment Alternatives
    • 58
    Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
    • 200
    Measures for Conducting Comparative Benefit: Risk Assessment
    • 18
    RISK VERSUS RISK: Decision-making Dilemmas of Drug Regulation in the United States and Germany
    • 31
    A scale for assessing the severity of diseases and adverse drug reactions; Application to drug benefit and risk
    • 25